Recent Updates
Recently added Catalysts

Syros Pharmaceuticals, Inc.

SYRSFDA catalysts, PDUFA dates & pipeline intelligence
$0
▲ +0 · +100%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SYRS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.1652W HIGH $7.96
Volume
851.00
Value Traded
0.09
Short % Float
0.03%
Days to Cover
1.0
+11.62%Week
-36.65%1 Month
-44.19%3 Month
-93.99%6 Month
-99.79%5 Year
-99.92%All Time

Cash Data

Unlock SYRS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.14 M
EPS (TTM)
-3.03
P/E Ratio
-
Ent. Value
6.92 M
Total Shares
26.83 M
Float Shares
23.92 M
Insiders
0.01%
Institutions
0.26%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every SYRS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SYRS Catalyst Timeline

Dated clinical, regulatory and corporate events for Syros Pharmaceuticals, Inc.

Unlock the full SYRS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SYRS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-11-15Tamibarotene Phase 3 data readout Phase 3
Unlock 1 more SYRS historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Showing 2 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SY-5609 Small moleculeCompletedNCT04247126Advanced Solid TumorPhase 1 COMPLETED 105Mar 30, 2023
Tamibarotene Small moleculeCompletedNCT02807558Acute Myeloid LeukemiaPhase 2 COMPLETED 155Jan 25, 2023
Unlock the SYRS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SYRS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
CTX001 sickle cell disease and beta thalassemia2020-12-0710 patients treated with CTX001, which demonstrated a consistent and sustained responseRead MoreASH 2020: CRISPR and Vertex’s Potential Cure for Sickle Cell Disease and More Glimmers of HopeRead More
Scroll for more · summaries link to the source press release
Unlock every SYRS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SYRS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Simonian Nancy ADirectorSell -37,070 4,000 held$0.27 12/02/2024
Unlock the full SYRS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in SYRS

Fund % of Portfolio Current MV Shares Owned Activity
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC 0.1 % (-83.3 %) 631.99 K 2.75 M
Unlock every fund holding SYRS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SYRS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SYRS ownership
Insider and institutional ownership, quarter by quarter.

SYRS Short Interest

Shares sold short, counted twice a month.

0.03%
Short % of Float
of tradable shares sold short
25.8K
Shares Sold Short
-0.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
26.5K
Avg Daily Volume
the average used for days to cover
Unlock SYRS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock SYRS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SYRS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SYRS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SYRS ranks across every disease it competes in

Competitive Position is a premium feature
See how SYRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SYRS News

About Syros Pharmaceuticals, Inc.

Ma, 02140 syros.com
Headquarters35 CambridgePark Drive, 4th Floor, Cambridge, MA, 02140, United States
Founded2016
BIOPHARMAWATCH ELITE PLUS
Trade the next SYRS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime